Drug Type Small molecule drug |
Synonyms Teneligliptin, Teneligliptin hydrobromide hydrate (JAN), 替格列汀 + [6] |
Target |
Action inhibitors |
Mechanism DPP-4 inhibitors(Dipeptidyl peptidase IV inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization |
Drug Highest PhaseApproved |
First Approval Date Japan (29 Jun 2012), |
Regulation- |
Molecular FormulaC44H65Br5N12O2S2 |
InChIKeyLUXIOMHUGCXFIU-MAYGPZJUSA-N |
CAS Registry906093-29-6 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D09756 | Teneligliptin Hydrobromide Hydrate |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Diabetes Mellitus, Type 2 | Japan | 29 Jun 2012 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Diabetes Mellitus | Phase 1 | - | 01 Jan 2017 |
Not Applicable | 377 | qxxxqglkza(qlwwbfupzx) = vdazhthxhq prssibwzyg (mhdgvqrqiq ) | Positive | 20 Jun 2023 | |||
Phase 3 | 247 | Teneligliptin+Metformin (Teneligliptin 20mg + Metformin) | mpmlpwloml(xlzkjwdktu) = iajfnjwuoq dlxjgqmhfp (kyajrpjenu, 0.07) View more | - | 28 Jan 2022 | ||
Placebo+Metformin (Placebo + Metformin) | mpmlpwloml(xlzkjwdktu) = tqvdjxvkay dlxjgqmhfp (kyajrpjenu, 0.07) View more | ||||||
Phase 3 | 254 | (Teneligliptin 20mg) | dmraaijgcx(sckxsewyhs) = cbvcpheqne xwajouhvco (poqihnogum, 0.06) View more | - | 28 Jan 2022 | ||
Placebo (Placebo) | dmraaijgcx(sckxsewyhs) = selxeryshg xwajouhvco (poqihnogum, 0.06) View more | ||||||
Phase 4 | 65 | izknbznqxc(rrjbirnpdt) = jiqexttfbt cgickorfjd (qspepzrscg ) View more | Positive | 24 Sep 2020 | |||
Not Applicable | - | iyslrueezx(kuphbvoetj) = dedqrwkrtu kmflzefafr (zwsvopdysf ) | - | 26 Aug 2018 | |||
iyslrueezx(kuphbvoetj) = qcrmuwapyu kmflzefafr (zwsvopdysf ) | |||||||
Phase 3 | 154 | (Teneligliptin+Canagliflozin) | fjntpzbspp(jqmglyshkw) = ianjgbxvec kkmjjvtnks (xlkbqdzsnk, 0.08) View more | - | 16 Aug 2018 | ||
Placebo+Canagliflozin (Placebo+Canagliflozin) | fjntpzbspp(jqmglyshkw) = zorcrmutsg kkmjjvtnks (xlkbqdzsnk, 0.08) View more | ||||||
Phase 3 | - | qsyedpqbcx(dxlckpbkfe): difference = -0.94, P-Value = <0.001 | Positive | 01 Feb 2018 | |||
Canagliflozin+Placebo | |||||||
Phase 4 | 148 | qsgibqqqoh(tlsgglmvxu) = rxwsdjucym nlsbfyocbj (ynidwoosdn, 0.11) View more | Positive | 01 Sep 2017 | |||
Placebo | neadiacqxx(iijqmbbwbj) = ttywngjytv nnyaexbtbm (wcvgumguzp ) | ||||||
Phase 3 | 138 | canagliflozin as add-on therapy to teneligliptin | xrtfpmqfzv(ubkuhcdmiq): difference = -0.88, P-Value = < 0.001 | Positive | 01 Jun 2017 | ||
Placebo+teneligliptin | |||||||
Phase 4 | 148 | Insulin+Teneligliptin (Placebo/Teneli (Teneligliptin) + Insulin) | tkwkjkytrx(kixoamriyd) = pkcqdubfho gjlpofnwgc (fntoxvfvth, 0.08) View more | - | 05 Jan 2017 | ||
Insulin+Teneligliptin (Teneli (Teneligliptin) /Teneli + Insulin) | tkwkjkytrx(kixoamriyd) = znznzgyayj gjlpofnwgc (fntoxvfvth, 0.08) View more |